Navigation Links
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Date:1/25/2010

section of novonordisk.com. Presentation material for the conference call will be made available approximately one hour before on the same page, and a replay of the conference call will be available approximately two hours after its conclusion.

Important Safety Information

Victoza causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice.  It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies.  Victoza is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).  Based on the findings in rodents, monitoring with serum calcitonin or thyroid ultrasound was performed during clinical trials, but this may have increased the number of unnecessary thyroid surgeries.  It is unknown whether monitoring with serum calcitonin or thyroid ultrasound will mitigate human risk of thyroid C-cell tumors.  Patients should be counseled regarding the risk and symptoms of thyroid tumors.

In clinical trials, there were more cases of pancreatitis among Victoza-treated patients than among comparator-treated patients.  If pancreatitis is suspected, Victoza should be discontinued.  Victoza should not be re-initiated if pancreatitis is confirmed.  Use with caution in patients with a history of pancreatitis.

When Victoza is used with an insulin secretagogue (e.g. a sulfonylurea) serious hypoglycemia can occur.  Consider lowering the dose of the insulin secretagogue to reduc
'/>"/>

SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SYDNEY and SOUTHAMPTON , ... -- Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology ... into a research collaboration to develop a selective inhibitor to ... fatal lung disease idiopathic pulmonary fibrosis (IPF). ... US. Current products are expected to produce global revenues in ...
(Date:8/4/2015)... VIEW, Calif. , Aug. 4, 2015  IRIDEX ... James H. Mackaness , who had served as chief ... since 2012, has resigned his positions with the Company, ... officer position at another company. Mr. Mackaness intends to ... Company,s second quarter earnings announcement and 10-Q filing. ...
(Date:8/4/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... ended June 30, 2015 and provided a summary ... second quarter of 2015 and recent period marked ... Paul Grint, M.D., President and CEO of Regulus. ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3IRIDEX Chief Financial Officer Resigns to Accept Another Opportunity 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10
... Reaffirms Primacy and Safety of ,First Generation, Antisense, ... (Nasdaq: GNTA ) announced the presentation of ... lead anticancer,compound, can be safely administered in high ... data were presented by Dr. Anthony Tolcher, Director,of ...
... - Studies Show Improvement in Hemodynamics and Delay ... Actelion Pharmaceuticals US, Inc.,today announced positive results from ... and effective as a combination therapy,for the treatment ... suggest that Tracleer, when given in combination with ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:8/5/2015)... , ... August 05, 2015 , ... ... have just published updated guidelines for the management of malignant pleural mesothelioma. Details ... to read the article. , The updated guidelines issued by the European ...
(Date:8/5/2015)... ... August 05, 2015 , ... Friendly Smiles Dental ... practice; Dr. Daniel H. Huynh, DMD and Dr. Michael J. Foley, DMD. The full ... patients at all three location in the Tampa Bay area, where Friendly Smiles Dental ...
(Date:8/5/2015)... ... ... Social Security benefits are not keeping pace with rising household budgets, according ... Citizens League (TSCL). The record low growth in cost-of-living adjustments (COLAs) in recent ... age 65 and older, says TSCL. , When asked to select between four statements ...
(Date:8/5/2015)... ... , ... Stelari introduces their new collection, The Earth’s Song, inspired by the ... Earth’s Song. Combining fashion and activewear, Stelari’s new collection let’s you take your bohemian ... this collection is sure to make the spirit seeker swoon with prints as meaningful ...
(Date:8/5/2015)... ... ... A leader in Primary Care Continuing Medical Education (CME), Continuing Education ... as its new Director of Program Management. , Su has over 16 years experience ... Primary Care Network (PCN) as the Director, Program Implementation as well as Supervisor of ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Treatment Guidelines Issued By European Researchers, According to Surviving Mesothelioma 2Health News:Friendly Smiles Dental Care Welcomes New Doctors 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 3Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 2Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 3
... Cancer At All Stages Steps Away From Home, ... ... Medical University of,South Carolina (MUSC) Foundation for Research and Development announced ... for bladder cancer have shown to be accurate for only 40 ...
... of,National Problem Gambling Awareness Week, the state departments ... of counseling,and treatment services available to those affected ... not only the gambler but also their family,and ... Commonwealth,of Pennsylvania is committed to addressing compulsive gambling ...
... 10 Medco Health,Solutions, Inc. (NYSE: MHS ) ... follows:, On Monday, March 17, 2008, Timothy C. ... Inc., Medco,s specialty pharmacy,subsidiary, is scheduled to address the ... at the Boston Marriott Copley,Place will begin at 1:45 ...
... health insurance programs do not provide coverage to international ... ... Seven Corners, one of the,industry,s most experienced travel health insurance ... they,plan to travel abroad for spring break vacations. Most health insurance,programs ...
... be getting them, study says , , MONDAY, March 10 (HealthDay ... choices for kidney cancer more than clinical factors such as ... finds. , This means many patients who are candidates ... where only part of the kidney is removed, may not ...
... ZARS Pharma, Inc. announced,today the completion of ... promotion and distribution rights for all markets ... (lidocaine and tetracaine) Cream,7%/7%, a topical anesthetic ... patients undergoing potentially painful cosmetic and other,skin ...
Cached Medicine News:Health News:Cell Receptor on Track for Painless Bladder Cancer Test 2Health News:State Agencies Highlight Available Assistance During Problem Gambling Awareness Week 2Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 3Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 7.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 7.7 mm....
Medicine Products: